MX2018009937A - Metodos y composiciones para administración de arisulfatasa a en el sistema nervioso central (cns). - Google Patents

Metodos y composiciones para administración de arisulfatasa a en el sistema nervioso central (cns).

Info

Publication number
MX2018009937A
MX2018009937A MX2018009937A MX2018009937A MX2018009937A MX 2018009937 A MX2018009937 A MX 2018009937A MX 2018009937 A MX2018009937 A MX 2018009937A MX 2018009937 A MX2018009937 A MX 2018009937A MX 2018009937 A MX2018009937 A MX 2018009937A
Authority
MX
Mexico
Prior art keywords
methods
arylsulfatase
compositions
cns delivery
cns
Prior art date
Application number
MX2018009937A
Other languages
English (en)
Inventor
Wasilewski Margaret
Wijatyk Anna
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of MX2018009937A publication Critical patent/MX2018009937A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se proporcionan métodos para el tratamiento de leucodistrofia metacromática que comprenden la administración a un sujeto que necesita tratamiento una cantidad con eficacia terapéutica de la enzima arilsulfatasa A recombinante.
MX2018009937A 2016-02-17 2017-02-17 Metodos y composiciones para administración de arisulfatasa a en el sistema nervioso central (cns). MX2018009937A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662296563P 2016-02-17 2016-02-17
US201762453864P 2017-02-02 2017-02-02
PCT/US2017/018440 WO2017143233A1 (en) 2016-02-17 2017-02-17 Methods and compositions for cns delivery of arylsulfatase a

Publications (1)

Publication Number Publication Date
MX2018009937A true MX2018009937A (es) 2018-11-29

Family

ID=58192404

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009937A MX2018009937A (es) 2016-02-17 2017-02-17 Metodos y composiciones para administración de arisulfatasa a en el sistema nervioso central (cns).

Country Status (10)

Country Link
US (2) US11020461B2 (es)
EP (1) EP3416678A1 (es)
JP (3) JP2019509270A (es)
CN (2) CN117224659A (es)
AU (1) AU2017220100B2 (es)
BR (1) BR112018016874A2 (es)
CA (1) CA3014909A1 (es)
MA (1) MA44237A (es)
MX (1) MX2018009937A (es)
WO (1) WO2017143233A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200384089A1 (en) * 2017-12-19 2020-12-10 Shire Human Genetic Therapies, Inc. Purified arylsulfatase a and compositons thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
CA2805413A1 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of heparan n-sulfatase
MX2020001395A (es) * 2010-06-25 2022-03-24 Shire Human Genetic Therapies Composiciones y su uso para suministro de iduronato-2-sulfatasa al sistema nervioso central.
KR102094094B1 (ko) * 2010-06-25 2020-03-27 샤이어 휴먼 지네틱 테라피즈 인크. 아릴설파타제 a의 cns 전달을 위한 방법들 및 조성물들
ES2650689T3 (es) * 2010-06-25 2018-01-19 Shire Human Genetic Therapies, Inc. Administración de agentes terapéuticos al sistema nervioso central

Also Published As

Publication number Publication date
JP2023159405A (ja) 2023-10-31
JP2021169528A (ja) 2021-10-28
CN117224659A (zh) 2023-12-15
WO2017143233A1 (en) 2017-08-24
AU2017220100B2 (en) 2024-04-04
CA3014909A1 (en) 2017-08-24
CN108883162A (zh) 2018-11-23
US20200179492A1 (en) 2020-06-11
EP3416678A1 (en) 2018-12-26
MA44237A (fr) 2021-06-02
JP2019509270A (ja) 2019-04-04
BR112018016874A2 (pt) 2019-02-05
US11020461B2 (en) 2021-06-01
US20210315981A1 (en) 2021-10-14
AU2017220100A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
PH12016501790A1 (en) Pharmaceutical compositions of therapeutically active compounds
WO2016106403A3 (en) Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
MX2021015427A (es) Vesiculas extracelulares microbianas procesadas.
PH12015500879A1 (en) Compositions and methods for treating proteinopathies
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
CA3081755A1 (en) Therapeutic cannabinoid formulations and methods for their use
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
MX2017011374A (es) Método de tratamiento de cáncer asociado con una mutación de ras.
GB2503852A (en) Compounds for the treatment of neuropsychiatric disorders
PH12020551427A1 (en) Epinephrine spray formulations
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
IL287715A (en) Useful preparations in the treatment of metachromatic leukodystrophy
DK2714888T3 (da) Rekombinant gær
MX2018007227A (es) Tratamiento de colestasis intrahepatica y enfermedades hepaticas relacionadas.
MX2018005352A (es) Metodos y composiciones para el tratamiento de amiloidosis.
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2016000448A (es) Péptidos y análogos peptídicos protectores de tejido para prevenir y tratar enfermedades y trastornos asociados con daño del tejido.
MX2019014867A (es) Metodo para tratar un efecto secundario de la inmunoterapia.
MX2018009937A (es) Metodos y composiciones para administración de arisulfatasa a en el sistema nervioso central (cns).